Clinical trials: Covid19- Coronavirus- Sars-cov-2
Covid19
ACTIV-6: COVID-19 Study of Repurposed Medications
The purpose of this study is to evaluate the effectiveness of repurposed medications (study drug(s) in reducing symptoms of non-hospitalized participants with mild to moderate COVID-19.
- Trial name
- NCT04885530
- Testing
- Ivermectin, Fluvoxamine, Fluticasone
- Where
- 110 sites in United States
- Volunteers
- 10,956 people
- Sponsor
- Susanna Naggie, MD
Coronavirus
Behavior, Environment And Treatments for Covid-19
Background: During the current COVID-19 pandemic there is urgent need for information about the natural history of the infection in non-hospitalized patients, including the severity and duration of symptoms, and outcome from…
- Trial name
- BEAT19 (NCT04321811)
- Testing
- Observation of patients with known, suspected, or at risk for COVID-19 infection
- Where
- United States
- Volunteers
- 5,000 people
- Sponsor
- xCures
COVID-19
Favipiravir Combined With Tocilizumab in the Treatment of Corona Virus Disease 2019
The purpose of this study is to evaluate the efficacy and safety of favipiravir combined with tocilizumab in the treatment of corona virus disease 2019.
- Trial name
- NCT04310228
- Testing
- Favipiravir Combined With Tocilizumab, Favipiravir, Tocilizumab
- Where
- 6 sites in China
- Volunteers
- 150 people
- Sponsor
- Peking University First Hospital
COVID-19
Evaluation of the Performance of Rapid Diagnostics for SARS-CoV-2 Self-testing in the Hands of Untrained
The aim of this study is to independently evaluate the usability and performance of rapid assays detecting SARS-CoV-2 antigen(s) and intended for self-testing.
- Trial name
- CV009 (NCT05605769)
- Where
- 2 sites in South Africa, Uganda
- Volunteers
- 3,266 people, healthy volunteers welcome
- Sponsor
- Foundation for Innovative New Diagnostics, Switzerland
SARS-CoV-2, Influenza A
POC Performance Evaluation of LumiraDx SARS-CoV-2 Ag Ultra and SARS-CoV-2 & Flu A/B Tests.
This is a prospective multicenter study conducted to evaluate the performance of the LumiraDx SARS-CoV-2 Ag Ultra test in detecting severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and LumiraDx SARS-CoV-2 \& Flu A/B…
- Conditions
- SARS-CoV-2, Influenza A, Influenza B, COVID-19
- Trial name
- PURSUE (NCT05728970)
- Testing
- LumiraDx SARS-CoV-2 Ag Ultra, LumiraDx SARS-CoV-2 & Flu A/B
- Where
- 10 sites in United States
- Volunteers
- 716 people, healthy volunteers welcome
- Sponsor
- LumiraDx UK Limited
Sars-CoV2, Critical Illness
COVID-19 and ICU-acquired MDR Bacteria
This multicenter before-after study aimed to determine the impact of infection related to SARS-CoV-2 on the incidence of ICU-acquired multidrug resistant (MDR) bacteria.
- Trial name
- COVID-BMR (NCT04378842)
- Where
- 7 sites in France
- Volunteers
- 368 people
- Sponsor
- University Hospital, Lille
COVID-19, SARS-CoV 2
Antiseptic Mouthwash / Pre-Procedural Rinse on SARS-CoV-2 Load (COVID-19)
In this pilot trial, 150 confirmed COVID-19 individuals will be randomly assigned to 1 of 5 groups: distilled water, CloSYS Ultra Sensitive Rinse (Rowpar Pharmaceutical Inc., USA), Oral-B Mouth Sore (Oral-B, USA), Crest…
- Conditions
- COVID-19, SARS-CoV 2, Severe Acute Respiratory Syndrome Coronavirus 2, Virus Disease
- Trial name
- AMPoL (NCT04409873)
- Testing
- Oral-B Mouth Sore mouthwash, Crest Pro-Health Multi-Protection mouthwash, CloSYS Ultra Sensitive Rinse mouthwash
- Where
- United States
- Volunteers
- 54 people
- Sponsor
- University of California, San Francisco
Safety, SARS-CoV2 Infection
Efficacy of Ivermectin in COVID-19
The newly emerged corona virus disease 2019 (COVID-19) has spread to all over the world, with recent estimates of more than 236 million cases diagnosed and led to 4.8 million deaths as November 20211 .Therapeutic approaches are…
- Conditions
- Safety, SARS-CoV2 Infection, Ivermectin Poisoning, Effect of Drug
- Trial name
- NCT05076253
- Testing
- Ivermectin
- Where
- Thailand
- Volunteers
- 72 people
- Sponsor
- Bangkok Metropolitan Administration Medical College and Vajira Hospital
Covid19
Retrospective Study of ImmunoFormulation for COVID-19
Multicentre, retrospective, observational study to describe the course of SARS-CoV-2 disease in patients treated or not with IMUNO TF ® and a combination of nutraceuticals and who have tested positive in a COVID-19 diagnostic…
- Trial name
- NCT04666753
- Testing
- ImmunoFormulation
- Where
- 2 sites in Spain
- Volunteers
- 40 people
- Sponsor
- Fagron Iberica S.A.U.
COVID-19, SARS-CoV 2
Canakinumab in Covid-19 Cardiac Injury (The Three C Study)
TThe purpose of this prospective, Phase 2, single center, blinded, randomized controlled study is to demonstrate as a proof of concept that early treatment with canakinumab prevents progressive heart and respiratory failure in…
- Trial name
- NCT04365153
- Testing
- Canakinumab Injection 600mg, Canakinumab Injection 300mg
- Where
- 2 sites in United States
- Volunteers
- 45 people
- Sponsor
- The Cleveland Clinic
Secondary Sclerosing Cholangitis, COVID-19
SSC-COVID in Patients After COVID-19
Analysis of occurrence of SSC-COVID in SARS-CoV-2-patients after the first wave of COVID-pandemic
- Trial name
- NCT05233553
- Testing
- control of liver enzymes
- Where
- Germany
- Volunteers
- 64 people
- Sponsor
- University Hospital Tuebingen
COVID-19
A Study to Evaluate Efficacy and Safety of the Combination of SCTA01 & SCTA01C in Outpatients With COVID-19
The study is comprised of two parts: safety evaluation part (Phase I/II) and the pivotal study (Phase III) to evaluate the efficacy and safety of the combination of SCTA01 \& SCTA01C compared to placebo in addition to Standard of…
- Trial name
- NCT05156645
- Testing
- SCTA01 and SCTA01C
- Sponsor
- Sinocelltech Ltd.
COVID-19, SARS-CoV Infection
Chloroquine Diphosphate in the Prevention of SARS in Covid-19 Infection
This is a double-blind, randomized, placebo-controlled clinical trial. A total of 210 individuals aged over 18 years old, without a diagnosis of severe respiratory disease, who came to the study site with clinical and…
- Conditions
- COVID-19, SARS-CoV Infection, Severe Acute Respiratory Syndrome (SARS) Pneumonia, Clinical Trial
- Trial name
- CloroCOVID19II (NCT04342650)
- Testing
- Chloroquine Diphosphate
- Where
- Brazil
- Volunteers
- 152 people
- Sponsor
- Fundação de Medicina Tropical Dr. Heitor Vieira Dourado
Coronavirus
COVID-19 Vaccine (ChAdOx1 nCoV-19) Trial in South African Adults With and Without HIV-infection
A Phase I/II, double-blinded, placebo-controlled, individually randomized trial to assess safety, immunogenicity and efficacy of the candidate Coronavirus disease (COVID-19) vaccine ChAdOx1 nCoV-19 in adults aged 18-65 years…
- Trial name
- NCT04444674
- Testing
- ChAdOx1 nCoV-19, Normal saline 0.9%
- Where
- 7 sites in South Africa
- Volunteers
- 2,130 people, healthy volunteers welcome
- Sponsor
- University of Oxford
Myalgic Encephalomyelitis, Long-COVID
Low Dose Rapamycin in ME/CFS, Long-COVID, and Other Infection Associated Chronic Conditions
The goal of this observational study is to assess the clinical response and the effect of autophagy function in patients before, during and throughout oral low dose sirolimus (rapamycin) therapy.
- Trial name
- NCT06257420
- Testing
- Rapamycin
- Where
- 5 sites in United States
- Volunteers
- 150 people
- Sponsor
- Simmaron Research Inc.
COVID 19
Anti COVID-19 Convalescent Plasma Therapy
Why is the research needed? The pandemic known as COVID-19 is now spreading across the world with currently (April 10, 2020) more than 1 115 530 active cases and 96 791 deaths.
- Trial name
- NCT04345679
- Testing
- anti-SARS-CoV-2 convalescent plasma
- Where
- Hungary
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Orthosera Kft.
SARS-CoV-2
A Study to Evaluate Safety and Effectiveness of mRNA-1273 COVID-19 Vaccine in Healthy Children Between 6 Months of Age and Less Than 12 Years of Age
The primary goal for this study is to evaluate up to 3 dose levels of mRNA-1273 vaccine given to healthy children as intramuscular (IM) injection in 2 doses (in Parts 1 and 2) and 3 doses (in Part 3), and a third dose or an…
- Trial name
- NCT04796896
- Testing
- mRNA-1273, mRNA-1273.214
- Where
- 91 sites in United States, Canada
- Volunteers
- 11,942 people, healthy volunteers welcome
- Sponsor
- ModernaTX, Inc.
Covid-19 Pneumonia, Cyotokine Storm
Adipose Mesenchymal Cells for Abatement of SARS-CoV-2 Respiratory Compromise in COVID-19 Disease
The aim of this study is to evaluate the safety and efficacy of autologous adipose-derived mesenchymal cells for treating confirmed or suspected patients with SARS-CoV-2 and compromised respiratory function requiring…
- Trial name
- NCT04352803
- Testing
- Autologous Adipose MSC's
- Volunteers
- 20 people
- Sponsor
- Regeneris Medical
SARS Virus, SARS-CoV-2
Convalescent Plasma and Placebo for the Treatment of COVID-19 Severe Pneumonia
A multicenter randomized, double-blind, placebo-controlled clinical trial of Convalescent SARS COVID-19 plasma versus Placebo to evaluate the effect between arms on an ordinal score of six mutually exclusive categories of…
- Conditions
- SARS Virus, SARS-CoV-2, COVID-19
- Trial name
- PLASM-AR (NCT04383535)
- Testing
- Convalescent SARS COVID-19 plasma
- Where
- Argentina
- Volunteers
- 333 people
- Sponsor
- Hospital Italiano de Buenos Aires
COVID-19
Study on Safety and Clinical Efficacy of AZVUDINE in COVID-19 Patients (SARS-CoV-2 Infected)
Estimated number of participants: 342 participants with COVID-19 Design: Phase III, single-center, randomized, double-blind, parallel, placebo-controlled clinical study.
- Trial name
- NCT04668235
- Testing
- AZVUDINE
- Where
- Brazil
- Volunteers
- 180 people
- Sponsor
- HRH Pharmaceuticals Limited
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.